JPRN-UMIN000035158
Recruiting
Phase 1
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study - PC(UR-M) GEM/nab-PTX + MK615
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- unresected/recurrent metastatic pancreatic cancer
- Sponsor
- Shimane University Hospital
- Enrollment
- 31
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Active concomitant malignancy or history of another malignancy within the last 5years (2\) Symptomatic brain metastasis (3\) Severe infectious diseases (4\) Subjects with the past history of Interstitial pneumonia or pulmonary fibrosis (5\) Subjects with the past history of severe heart disease (6\) Severe Paresthesia or Sensory disorder with motor dysfunction (7\) Severe pleural effusion, ascites, or pericardial effusion (8\) Subjects with the past history of severe diseases (kidney disease,liver disease, heart disease). (9\) History of Radiation therapy for pancrearic cancer (10\) Symptomatic brain metastases or Clinically suspected brain metastases. (11\) Men/Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (12\) Inappropriate to be enrolled in this study judged by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35
Completed
Not Applicable
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancerunresectable pancreas cancerJPRN-UMIN000013206Yokohama City University Hospital Oncology
Completed
Not Applicable
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasisThe patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.JPRN-UMIN000018878Study group of pancreatic cancer with peritoneal metastasis48
Active, not recruiting
Phase 1
Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma - GABRINOXEUCTR2012-003678-13-FRInstitut Régional de Cancerologie de Montpellier - Val d’Aurelle118
Completed
Phase 2
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24